Coro Global (CGLO) 10-K 2 Apr 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 31, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	Medefile International, Inc.
Entity Central Index Key	842013
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Document Type	10-K
Document Period End Date	31-Dec-14
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$1,500,000
Entity Common Stock, Shares Outstanding		522,953,672

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets
Cash	$36,170	$266,843
Accounts receivable	5,425	2,914
Inventory	23,412	54,507
Merchant services reserve	2,939	14,818
Prepaid expense	5,709	1,057
Total current assets	73,655	340,139
Website development, net of accumulated amortization	265,792	261,340
Furniture and equipment, net of accumulated depreciation		413
Intangibles		1,339
Total assets	339,447	603,231
Current Liabilities
Accounts payable and accrued liabilities	47,697	52,915
Coverible debenture - net of discount	122,538	9,177
Deferred revenues	684	2,075
Derivative liability	51	1,062,141
Total Current Liabilities	170,970	1,126,308
Stockholders' (Deficit)
Preferred stock, $.0001 par value: 10,000,000 authorized, no shares issued and outstanding
Common stock, $.0001 par value: 500,000,000 authorized; 225,836,554 and 40,706,899 shares issued and outstanding on December 31, 2014 and December 31, 2013, respectively	22,583	4,070
Additional paid in capital	27,430,517	27,099,030
Common stock to be issued	69,920	69,920
Accumulated deficit	-27,354,543	-27,696,097
Total stockholders' (deficit)	168,477	-523,077
Total liability and stockholders'(deficit)	$339,447	$603,231

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	225,836,554	40,706,899
Common stock, shares outstanding	225,836,554	40,706,899

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Revenue	$75,988	$40,059
Cost of goods sold	1,095	1,331
Gross profit	74,893	38,728
Operating expenses
Selling, general and administrative expenses	650,316	962,156
Depreciation and amortization expenses	1,752	6,362
Total operating expenses	652,068	968,518
Loss from operations	-577,175	-929,790
Other income (expenses)
Interest expense - convertible note	-11,525	-1,013
Interest expense - discount on convertible note	-101,836	-8,164
Loss on write-off of inventory	-30,000
Change of derivative liabilities	1,062,090	2,366,218
Total other income (expense)	918,729	2,357,041
Gain (loss) before income tax	341,554	1,427,251
Provision for income tax
Net income (loss)	$341,554	$1,427,251
Net loss per share: basic and diluted	$0	$0.07
Weighted average share outstanding basic and diluted	80,626,245	21,232,854

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity (USD $)	Total	Preferred	Common Stock	APIC	Common Stock Payable	Accumulated Deficit
Beginning Balance at Dec. 31, 2012	($5,235,708)		$1,141	$23,886,499		($29,123,348)
Beginning Balance (in shares) at Dec. 31, 2012			11,413,189
Common stock sale	915,000		1,742	913,258
Common stock sale (in shares)			17,421,429
Adjustment to derivative liability			2,190,460			2,190,460
Covertible debenture discount	110,000			110,000
Common stock issued for anti-dilution			1,187	-1,187
Common stock issued for anti-dilution (in shares)			11,872,281
Common stock payable	69,920				69,920
Net income	1,427,251					1,427,251
Ending Balance at Dec. 31, 2013	-523,077		4,070	27,099,030	69,920	-27,696,097
Ending Balance (in shares) at Dec. 31, 2013			40,706,899
Common stock sale	350,000		3,500	346,500
Common stock sale (in shares)			35,000,000
Common stock issued for anti-dilution			15,013	-15,013
Common stock issued for anti-dilution (in shares)			150,129,655
Net income	341,554					341,554
Ending Balance at Dec. 31, 2014	$168,477		$22,583	$27,430,517	$69,920	($27,354,543)
Ending Balance (in shares) at Dec. 31, 2014			225,836,554

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities
Net income	$341,554	$1,427,251
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	413	1,116
Amortization	1,339	5,245
Interest expense - discount on convetible debenture	101,836	8,164
Loss on write-off of inventory	30,000
(Gain)loss in fair value of derivitave liabilities	-1,062,090	-2,366,218
Changes in operating assets and liabilities
Accounts receivable	-2,511	-2,523
Inventory	61,095	951
Prepaid insurance	-4,652	-59
Accounts payable and accrued liabilities	-5,218	-85,296
Interest expense - covertible debenture	11,525	1,013
Merchant service reserves	11,879	49,501
Deferred revenue	-1,391	-2,238
Net Cash used in operating activities	-576,221	-963,093
Cash flows from investing activities
Website development	-4,452	-99,340
Net cash used in investing activities	-4,452	-99,340
Cash flow from financing activities
Proceeds fromm convertible debenture - related party		110,000
Proceeds from common stock subscriptions	350,000	984,920
Net cash provided by financing activities	350,000	1,094,920
Net increase (decrease) in cash and cash equivalents	-230,673	32,487
Cash and cash equivalents at beginning of period	266,843	234,356
Cash and cash equivalents at end of period	36,170	266,843
Supplemental disclosure of cash flow information
Cash paid for interest
Cash paid for income taxes

Basis_of_Presentation_and_Natu

Basis of Presentation and Nature of Business Operations	12 Months Ended
	Dec. 31, 2014
Basis of Presentation and Nature of Business Operations [Abstract]
BASIS OF PRESENTATION AND NATURE OF BUSINESS OPERATIONS	1. BASIS OF PRESENTATION AND NATURE OF BUSINESS OPERATIONS
	Basis of Presentation
	The accompanying financial statements present on a consolidated basis the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation
	Nature of Business Operations
	Medefile International, Inc. has developed and globally markets a proprietary, patient-centric, Internet-enabled Personal Health Record (iPHR) system for gathering, digitizing, maintaining, accessing and sharing an individual’s actual medical records. Medefile's goal is to revolutionize the medical industry by bringing patient-centric digital technology to the business of medicine. Medefile intends to accomplish its objective by providing individuals with a simple and secure way to access their lifetime of actual medical records in an efficient and cost-effective manner. Medefile's products and services are designed to provide healthcare providers with the ability to reference their patients’ actual past medical records, thereby ensuring the most accurate treatment and services possible while simultaneously reducing redundant procedures.
	Interoperable with most electronic medical record systems utilized by physician practices, clinics, hospitals and other care providers, the highly secure, feature-rich MedeFile iPHR solution has been designed to gather all of its members’ actual medical records on behalf of each member, and create a single, comprehensive Electronic Health Record (EHR). The member can access his/her records 24-hours a day, seven days a week – or authorize a third party user – on any web-enabled device (PC, cell phone, PDA, e-reader, et al), as well as the portable MedeFile flash drive/keychain or branded UBS-bracelet.
	By subscribing to the MedeFile system, members empower themselves to take control of their own health and well-being, and empower their healthcare providers to make sound and lifesaving decisions with the most accurate, up-to-date medical information available.  In addition, with MedeFile, members enjoy the peace of mind that comes from knowing that their medical records are protected from fire, natural disaster, document misplacement or the closing of a medical or dental practice.
	MedeFile believes it enjoys a number of competitive advantages over other firms within the medical records marketplace, including:
	·	MedeFile has developed products and services geared to the patient, while containing the depth and breadth of information required by treating physicians and medical personnel.
	·	MedeFile does all the work of collecting and updating medical information on an ongoing basis; the function of our products’ dependence on the patient taking action is minimal – particularly when compared to patient action required to support competing solutions.
	·	MedeFile provides a complete medical record. Other companies claim complete longitudinal records, but in reality only provide histories (usually completed by the member/patient), which are by no means complete or necessarily accurate records.
	·	MedeFile provides a coherent mix of services and products that are intended to improve the quality of healthcare by enabling the patient to manage and access the information normally retained by doctors and other care providers.
	Going Concern
	The accompanying financial statements have been prepared contemplating a continuation of the Company as a going concern. However, the Company has reported an operating loss of $577,175 and net income of $341,554 for the year ended December 31, 2014. During the comparable year ended 2013, the Company had an operating loss of $922,790 and net income of $1,427,251, as a direct result of the change in valuation of the Company’s warrant derivative. The Company had an accumulated deficit of $27,354,543 as of December 31, 2014.  The Company has negative working capital of $97,315 as of December 31, 2014.
	The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The operating losses raise substantial doubt about the Company's ability to continue as a going concern. The Company's ability to obtain additional financing depends on the availability of its borrowing capacity, the success of its growth strategy and its future performance, each of which is subject to general economic, financial, competitive, legislative, regulatory, and other factors beyond the Company's control.
	We will need additional investments in order to continue operations to cash flow break even. Additional investments are being sought, but we cannot guarantee that we will be able to obtain such investments. Financing transactions may include the issuance of equity or debt securities, obtaining credit facilities, or other financing mechanisms.
	However, the trading price of our common stock could make it more difficult to obtain financing through the issuance of equity or debt securities. Even if we are able to raise the funds required, it is possible that we could incur unexpected costs and expenses, fail to collect significant amounts owed to us, or experience unexpected cash requirements that would force us to seek alternative financing. Further, if we issue additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our common stock. If additional financing is not available or is not available on acceptable terms, we will have to curtail our operations.
	Cash and Cash Equivalents
	For purposes of these financial statements, cash and cash equivalents includes highly liquid debt instruments with maturity of less than three months.
	Concentrations of Credit Risk
	Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit. Currently our operating account is not above the FDIC limit.
	Advertising
	The Company follows the policy of charging the costs of advertising to expense as incurred. The Company incurred advertising costs for the year ended December 31, 2014 and 2013 of approximately $0 and $0 respectively.
	Income Taxes
	The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.
	The Company records net deferred tax assets to the extent the Company believes these assets will more likely than not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. A valuation allowance is established against deferred tax assets that do not meet the criteria for recognition. In the event the Company were to determine that it would be able to realize deferred income tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes.
	The Company follows the accounting guidance which provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more-likely-than-not recognition threshold at the effective date to be recognized initially and in subsequent periods. Also included is guidance on measurement, recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.
	Property and Equipment
	Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. Minor additions and renewals are expensed in the year incurred. Major additions and renewals are capitalized and depreciated over their estimated useful lives being 3 years up to 10 years.
	Trademark Costs
	Trademark costs incurred in the registration and acquisition of trademarks and trademark rights are capitalized. These costs will be amortized over the legal life of the related trademark once the trademark is awarded. The Company performs an annual review of its identified intangible assets to determine if facts and circumstances exist which indicate that the useful life is shorter than originally estimated or that the carrying amount of the assets may not be recoverable.
	The Company expenses all software costs associated with the conceptual formulation and evaluation of alternatives until the application development stage has been reached. Costs to improve or support the technology are expensed as these costs are incurred.
	Website Development
	The Company's policy is to capitalize website development costs at original cost and amortize the balance over the life of the product. The life of website is determined at completion of the project. The Company reviews the amounts capitalized for impairment whenever events or circumstances indicate that the carrying amounts of the assets may not be recoverable.
	The Company expenses all development costs associated with the conceptual formulation and evaluation of alternatives until the application development stage has been reached. Costs to improve or support the technology are expensed as these costs are incurred.
	Revenue Recognition
	The Company generates revenue from licensing the right to utilize its proprietary software for the storage and distribution of healthcare information to individuals and affinity groups. For revenue from product sales, the Company recognizes revenue on four basic criteria which must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management's judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.
	Deferred Revenue
	The Company generally receives subscription fees for its services. From time to time, the Company will receive quarterly or annual subscriptions paid in advance and deferred revenue is recorded at that time. The deferred revenue is amortized into revenue on a pro- rata basis each month. Customers with quarterly or annual subscriptions may cancel their subscriptions and request a refund for future months' revenues at any time. Therefore, a liability is recorded to reflect the amounts that are potentially refundable. At December 31, 2014 and December 31, 2013, deferred revenue totaled $684 and $2,075, respectively.
	Reclassifications
	Certain reclassifications have been made in prior periods financial statements to conform to classifications used in the current period.
	Recent Accounting Pronouncements
	In August 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Updates (ASU) 2014-15 requiring an entity’s management to evaluate whether there are conditions or events, considered in aggregate, that raise substantial doubt about entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted.
	Fair Value of Financial Instruments
	Cash and Equivalents, Deposits In-Transit, Receivables, Prepaid and Other Current Assets, Accounts Payable, Accrued Salaries and Wages and Other Current Liabilities
	The carrying amounts of these items approximated fair value.
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, Financial Accounting Standards Board (“FASB”) ASC Topic 820-10-35 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurements).
	Level 1—Valuations based on quoted prices for identical assets and liabilities in active markets.
	Level 2—Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.
	Level 3—Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.
	The application of the three levels of the fair value hierarchy under Topic 820-10-35 to our assets and liabilities are described below:
					Fair Value Measurements
					Level 1		Level 2		Level 3	Total
			Assets
			Website development	$	-	$	-	$	265,792	$265,792
			Total	$	-	$	-	$	265,792	$265,792
			Liabilities
			Deferred Revenues	$	684	$	-	$	-	$684
			Derivative Liability		-		-		51	51
			Total	$	684	$	-	$	51	$735
	Impairment of Long Lived Assets
	In accordance with Accounting Standards Codification (“ASC”) 360-10, Accounting for the Impairment or Disposal of Long-Lived Assets, long-lived assets to be held and used are analyzed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. ASC 360-10 relates to assets that can be amortized and the life can be determinable. The Company reviews property and equipment and other long-lived assets for impairment annually, or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the asset’s carrying amount to future undiscounted net cash flows the assets are expected to generate. Cash flow forecasts are based on trends of historical performance and management's estimate of future performance, giving consideration to existing and anticipated competitive and economic conditions. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future cash flows arising from the assets or their fair values, whichever is more determinable.
	Inventory
	Inventories are stated at the lower of cost or market value. Cost is determined by the first-in, first-out basis and market being determined as the lower of replacement cost or net realizable value. The Company records inventory write-downs for estimated obsolescence of unmarketable inventory based upon assumptions about future demand and market conditions. For the year ended December 31, 2014 the Company had an inventory write off of $30,000. There was no inventory write off for the year ended December 31, 2013.
Net Loss per Share
Basic and diluted loss per share amounts are computed based on net loss divided by the weighted average number of common shares outstanding. Warrants to purchase 3,010,511 common shares were not included in the computation of diluted loss per share because the assumed conversion and exercise would be anti-dilutive for the year ending December 31, 2014.
Management Estimates
The presentation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported period. Actual results could differ from those estimates.
Stock Based Compensation
The Company accounts for all compensation related to stock, options or warrants using a fair value based method whereby compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. The Company uses the Black-Scholes pricing model to calculate the fair value of options and warrants issued to both employees and non-employees. Stock issued for compensation is valued using the market price of the stock on the date of the related agreement.

Accounts_Receivable

Accounts Receivable	12 Months Ended
	Dec. 31, 2014
Accounts Receivables [Abstract]
ACCOUNTS RECEIVABLE	2.  ACCOUNTS RECEIVABLE
	Due to the collection history of the Company, the Company does not maintain an allowance for doubtful accounts.  Recognition of a specific uncollectible account is written directly against the invoice in accounts receivable and expensed in the current period.

Website_Development

Website Development	12 Months Ended
	Dec. 31, 2014
Website Development [Abstract]
WEBSITE DEVELOPMENT	3. WEBSITE DEVELOPMENT
	Website development consists of the following:
			December 31,			31-Dec-13
			2014
	Website development	$	324,285		$	224,946
	Additional development		4,453			99,340
	Accumulated amortization		(62,946	)		(62,946	)
	Net website development	$	265,792		$	261,340
	During May 2012 the Company began redesigning its website.  The Company anticipates that the redesign will be completed by June 2015.
	Amortization is calculated over a three-year period. Amortization expense for the year ending December 31, 2014 and 2013 is $1,339 and $5,245, respectively.

Furniture_and_Equipment

Furniture and Equipment	12 Months Ended
	Dec. 31, 2014
Furniture and Equipment [Abstract]
FURNITURE AND EQUIPMENT	4. FURNITURE AND EQUIPMENT
	Furniture and equipment consists of the following:
		31-Dec-14			December 31,
					2013
	Computers and equipment	$	169,286		$	169,286
	Furniture and fixtures		38,618			38,618
	Subtotal		207,904			207,904
	Less: accumulated depreciation		(207,904	)		(207,491	)
	Net furniture and equipment	$	-		$	413
	Depreciation is calculated by using the straight-line method over the estimated useful life.  Depreciation expense totaled $413 and $1,116 for the year ended December 31, 2014 and 2013, respectively.

Convertible_Debebture_Related_

Convertible Debebture - Related Party	12 Months Ended
	Dec. 31, 2014
Convertible Debebture - Related Party [Abstract]
CONVERTIBLE DEBEBTURE - RELATED PARTY	5. CONVERTIBLE DEBEBTURE – RELATED PARTY
	The Company entered into two 10% Secured Convertible Debentures with a significant shareholder. The debentures carry a one year term. The debentures were issued in the amount of $50,000 on November 4, 2013 and $60,000 on December 17, 2013. Both debentures have a conversion feature at a share price of $0.10. The Company recognized a beneficial conversion feature (BCF) due to the intrinsic value of the conversion rate compared to the market price of the common stock as of the grant date. A discount is computed based on the share value at the time of issuance and amortized over the period of the debenture.
		31-Dec-14		December 31,
				2013
	Convertible debenture – related party	$	122,538	$	111,013
	Beneficial conversion feature		-		(101,836	)
	Convertible debenture, net of BCF	$	122,538	$	9,177

Warrant_Liability

Warrant Liability	12 Months Ended
	Dec. 31, 2014
Warrant Liability [Abstract]
WARRANT LIABILITY	6. WARRANT LIABILITY
	In connection with certain securities purchase agreements entered into during the third quarter of 2011 and the second quarter of 2012 (see Note 7), the Company granted warrants with ratchet provisions. The warrants contain an expiration date of four years from the date of grant. During the first two years of grant, if the Company issues any additional shares of common stock at a price per share less than the exercise price in effect, the exercise price will be adjusted to equal the average price per share received by the Company for the additional shares issued. After the first two years, if the Company issues any additional shares of common stock at a price per share less than the exercise price in effect, the exercise price will be adjusted using a formula based on the existing exercise price, the outstanding shares before and after the issuance of such shares, and the average price during the issuance of such shares. In addition to the exercise price adjustment, the number of shares upon exercise of the warrants is also subject to adjustment.
	Upon grant, the Company assesses the fair value of the warrants using the Black Scholes pricing model and records a warrant liability for the value. The Company then assesses the fair value of the warrants quarterly based on the Black Scholes Model and increases or decreases the warrant liability to the new value, and records a corresponding gain or loss. The Company uses expected volatility based primarily on historical volatility using weekly pricing observations for recent periods that correspond to the expected life of the warrants. The risk-free interest rate is based on U.S. Treasury securities rates.
	Due to the ratchet provisions, the Company treats the warrants as a derivative liability in accordance with the provisions of ASC 815 “Derivatives and Hedging” (ASC 815). ASC 815 applies to any freestanding financial instruments or embedded features that have the characteristics of a derivative and to any freestanding financial instruments that potentially settle in an entity’s own common stock.
	As of December 31, 2014, these warrants include the following:
	Warrants granted during July 2011 in connection with the sale of 35,461 shares of common stock with the right to originally purchase up to 35,461 shares of the Company’s common stock with an original exercise price of $2.50. Due to the issuance of the Company’s common stock in April 2012, the exercise price was adjusted to $0.50 and the number of shares to 1,808,511. Fair value was determined using the following variables:
		Grant Date			31-Dec-14
	Risk-free interest rate at grant date		1.21	%		1.38	%
	Expected stock price volatility		194.9	%		143.1	%
	Expected dividend payout		-			-
	Expected option in life-years		4			51
	Warrants granted during April 2012 in connection with the sale of 100,000 shares of the Company’s preferred stock to a significant shareholder and brother of the Chief Executive Officer with the right to purchase up to 200,000 shares of the Company’s common stock with an exercise price of $0.50. Fair value was determined using the following variables:
		Grant Date			31-Dec-14
	Risk-free interest rate at grant date		0.64	%		0	%
	Expected stock price volatility		174.3	%		143.1	%
	Expected dividend payout		-			-
	Expected option in life-years		4			1.28
	Warrants granted during April 2012 in connection with the sale of 1,000,000 shares of the Company’s common stock with an exercise price of $0.50.
		Grant Date			31-Dec-14
	Risk-free interest rate at grant date		0.63	%		0	%
	Expected stock price volatility		174.8	%		143.1	%
	Expected dividend payout		-			-
	Expected option in life-years		4			1.3
	Transactions involving warrants with ratchet provisions are as follows:
		Number of Warrants			Weighted-Average Price Per Share
	Outstanding at December 31, 2011		3,008,511		$	0.5
	Granted
	Exercised
	Canceled or expired
	Additional due to ratchet trigger
	Outstanding at December 31, 2013		3,008,511			0.5
	Granted
	Exercised
	Canceled or expired
	Addition due to ratchet trigger
	Outstanding at December 31, 2014		3,008,511		$	0.5
	As of December 31, 2014 and December 31, 2013, the warrant liability consisted of the following:
		31-Dec-14			December 31,
					2013
	Warrant liability (beginning balance)	$	5,618,819		$	5,618,819
	Additional liability due to new grants
	Loss(gain) on changes in fair market value of warrant liability		(5,618,768	)		(4,556,678	)
	Net warrant liability	$	51		$	1,062,141
	Change in fair market value of warrant liability resulted in a gain totaling $1,062,090 and $2,366,218 for the years ended December 31, 2014 and 2013, respectively.

Equity

Equity	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
EQUITY	7. EQUITY
	Common Stock
	On October 8, 2012, the Company filed a Certificate of Amendment to its Articles of Incorporation with the Secretary of State of Nevada, pursuant to which (i) the Company effected a 5,000-to-1 reverse split of its common stock and (ii) the number of authorized shares of the Company’s common stock decreased from 75,000,000,000 to 100,000,000. The market effective date of the reverse split was October 9, 2012.  The effect of the stock split has been applied retroactively. On December 19, 2013 the Company increased its authorized shares of common stock from 100,000,000 to 500,000,000.
	2013
	On January 17, 2013 the Company entered into a Securities Purchase Agreement pursuant to which the Company sold 400,000 shares of common stock for an aggregate purchase price of $200,000
	On April 15, 2013, the Company entered into a Securities Purchase Agreement with accredited investors pursuant to which the Company sold 2,000,000 shares of common stock for an aggregate purchase price of $400,000.
	On May 1, 2013 the Company issued an aggregate of 11,872,281shares of common stock to purchasers under the securities purchase agreements entered into by the Company in July 2011 and April 2012 pursuant to anti-dilution rights held by such purchasers.
	On August 27, 2013, the Company entered into a Securities Purchase Agreement with accredited investors pursuant to which the Company sold 42,743 shares of common stock for an aggregate purchase price of $29,920.
	On September 23, 2013, the Company entered into a Securities Purchase Agreement with accredited investors pursuant to which the Company sold 21,429 shares of common stock for an aggregate purchase price of $15,000.
	On December 17, 2013, the Company entered into a Securities Purchase Agreement with accredited investors pursuant to which the Company sold 2,000,000shares of common stock for an aggregate purchase price of $40,000. The shares are currently unissued
	On December 20, 2013, the Company entered into a Securities Purchase Agreement with accredited investors pursuant to which the Company sold 15,000,000 shares of common stock for an aggregate purchase price of $300,000.
	2014
	On April 17, 2014, the Company issued an aggregate of 150,129,655 shares of common stock to certain shareholders of the Company, in accordance with anti-dilution rights held by such shareholders, including 125,584,200 shares to Lyle Hauser and 24,545,455 shares to purchasers under Securities Purchase Agreements entered into by the Company in July 2011. Lyle Hauser is the Company's largest shareholder.
	On July 3, 2014, the Company entered into a Securities Purchase Agreement with accredited investors pursuant to which the Company sold 15,000,000 shares of common stock for an aggregate purchase price of $200,000.
	On July 6, 2014, the Company entered into a Securities Purchase Agreement with accredited investors pursuant to which the Company sold 20,000,000 shares of common stock for an aggregate purchase price of $150,000.
	Preferred Stock
	On April 10, 2012, the Company filed a certificate of designation of Series B Preferred Stock (the “Series B Certificate of Designation”) with the Secretary of State of Nevada, pursuant to which 100,000 shares of the Company’s preferred stock were designated as Series B Convertible Preferred Stock (the “Series B Preferred Stock”).  Pursuant to the Series B Certificate of Designation, the Series B Preferred Stock:
	●	Has a liquidation preference over the common stock equal to the stated value of $1.00 per share.
	●	Votes as a single class with the common stock and entitles its holders, for each share of Series B Preferred Stock, to cast such number of votes equal to 0.00051% of the total number of votes entitled to be cast. Accordingly, a holder of all 100,000 shares of Series B Preferred Stock will have the right to cast 51% of the total number of votes entitled to be cast.
	●	Will automatically convert into common stock at a ratio of 2 shares of common stock for each share of Series B Preferred Stock, effective upon the Company’s filing of a certificate of amendment to its articles of incorporation.
	On April 12, 2012, the Company entered into a securities purchase agreement with Lyle Hauser (the “Preferred Stock Investor”). Lyle Hauser is the Company’s largest shareholder and the brother of Kevin Hauser, the Company’s then-chief executive officer. Pursuant to the purchase agreement, on April 12, 2012, the Company sold 100,000 shares of Series B Preferred Stock to the Preferred Stock Investor for an aggregate purchase price of $100,000, and the Company issued four-year warrants to purchase 200,000 shares of common stock to the Preferred Stock Investor with an exercise price of $0.50. On April 23, 2012, 100,000 Series B Preferred shares were converted to 200,000 shares of common stock
	Stock Options
	2006 Incentive Stock Plan
	In January 2006, the Board of Directors of the Company approved an Incentive Stock Plan, pursuant to which they have initially reserved 10,000,000 shares of common Stock for issuance. Under the 2006 Incentive Stock, the Board has granted an aggregate of 5,640,000 options to employees pursuant to certain employment agreements. All previously granted options have expired unexercised.
	2008 Amended and Restated Incentive Stock Plan
	In November 2008, our Board of Directors adopted the 2008 Equity Incentive Plan and subsequently amended it in January 2009, June 2009 and July 2009 (the “2008 Plan”). The purpose of the 2008 Plan was to provide an incentive to attract and retain directors, officers, consultants, advisors and employees whose services are considered valuable, to encourage a sense of proprietorship and to stimulate an active interest of such persons into our development and financial success. Under the 2008 Plan, the Company is authorized to issue incentive stock options intended to qualify under Section 422 of the Code, non-qualified stock options, stock appreciation rights, performance shares, restricted stock and long term incentive awards. The 2008 Plan will be administered by our Board of Directors until such time as such authority has been delegated to a committee of the board of directors.
	2010 Incentive Stock Plan
	In December 2009, our Board of Directors adopted the 2010 Equity Incentive Plan (the “2010 Plan”). The purpose of the 2010 Plan was to provide an incentive to attract and retain directors, officers, consultants, advisors and employees whose services are considered valuable, to encourage a sense of proprietorship and to stimulate an active interest of such persons into our development and financial success. Under the 2010 Plan, we are authorized to issue incentive stock options intended to qualify under Section 422 of the Code, non-qualified stock options, stock appreciation rights, performance shares, restricted stock and long term incentive awards. The 2010 Plan will be administered by our Board of Directors until such time as such authority has been delegated to a committee of the Board of Directors.
	Other Warrants
	During the first quarter of 2008 the Company awarded 35 Common Stock warrants, at an exercise price of $2,800 per share, to former Board members at the quoted stock price on the effective date of the awards. The warrants have an expiration date of five years from the issue date and contain provisions for a cash exercise. The estimated value of the compensatory warrants granted to non-employees in exchange for services and financing expenses was determined using the Black-Scholes pricing model and the following assumptions:
	Risk-free interest rate at grant date			4.75	%
	Expected stock price volatility			155	%
	Expected dividend payout			--
	Expected option in life-years			5
	On June 22, 2011, the Company awarded 2,000 Common Stock warrants, at an exercise price of $50 per share, to consultants for services at the quoted stock price on the effective date of the awards. The warrants have an expiration date of four years from the issue date and contain provisions for a cash exercise. The estimated value of the compensatory warrants granted to non-employees in exchange for services and financing expenses was determined using the Black-Scholes pricing model and the following assumptions listed below:
	On July 28, 2011, the Company awarded 27,000 Common Stock Warrants, at an exercise price of $25 per share to consultants for services at the quoted stock price on the effective date of the awards. The warrants have an expiration date of three years from the issue date and contain provisions for a cash exercise. The estimated value of the compensatory warrants granted to non-employees in exchange for services was determined using the Black-Scholes pricing model and the assumptions listed below. These warrants have expired as of December 31, 2014.
	Risk-free interest rate at grant date			0.39	%
	Expected stock price volatility			172.1	%
	Expected dividend payout			--
	Expected option in life-years			4
	Transactions involving warrants are summarized as follows:
			Number of Warrants			Weighted-Average Price Per Share
	Outstanding at December 31, 2012			29,000			30.07
	Granted			-			-
	Exercised			-			-
	Canceled or expired			-			-
	Outstanding at December 31, 2013			29,000		$	26.72
	Granted			-			-
	Exercised			-			-
	Canceled or expired			-27,000			25
	Outstanding at December 31, 2014			2,000		$	50
	Warrants Outstanding
						Weighted
						Average
						Remaining
	Exercise		Number			Contractual
	Prices			Outstanding			Life (years)
	$50			2,000			0.75
	50			2,000			0.75

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	8. RELATED PARTY TRANSACTIONS
	None.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	8.  SUBSEQUENT EVENTS
	On February 10, 2015 the Company increased its authorized shares of common stock from 500,000,000 to 700,000,000.
	During the first quarter of 2015, the Company issued an aggregate of 279,099,100 shares of common stock to purchasers under the securities purchase agreements entered into by the Company in January and February 2015 for aggregate price of $620,000, and the Company issued 18,018,018 shares of common stock to Lyle Hauser in exchange for $40,000 of debt owed by the Company to Mr. Hauser.

Basis_of_Presentation_and_Natu1

Basis of Presentation and Nature of Business Operations (Policies)	12 Months Ended
	Dec. 31, 2014
Basis of Presentation and Nature of Business Operations [Abstract]
Basis of Presentation	Basis of Presentation
	The accompanying financial statements present on a consolidated basis the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation
Nature of Business Operations	Nature of Business Operations
	Medefile International, Inc. has developed and globally markets a proprietary, patient-centric, Internet-enabled Personal Health Record (iPHR) system for gathering, digitizing, maintaining, accessing and sharing an individual’s actual medical records. Medefile's goal is to revolutionize the medical industry by bringing patient-centric digital technology to the business of medicine. Medefile intends to accomplish its objective by providing individuals with a simple and secure way to access their lifetime of actual medical records in an efficient and cost-effective manner. Medefile's products and services are designed to provide healthcare providers with the ability to reference their patients’ actual past medical records, thereby ensuring the most accurate treatment and services possible while simultaneously reducing redundant procedures.
	Interoperable with most electronic medical record systems utilized by physician practices, clinics, hospitals and other care providers, the highly secure, feature-rich MedeFile iPHR solution has been designed to gather all of its members’ actual medical records on behalf of each member, and create a single, comprehensive Electronic Health Record (EHR). The member can access his/her records 24-hours a day, seven days a week – or authorize a third party user – on any web-enabled device (PC, cell phone, PDA, e-reader, et al), as well as the portable MedeFile flash drive/keychain or branded UBS-bracelet.
	By subscribing to the MedeFile system, members empower themselves to take control of their own health and well-being, and empower their healthcare providers to make sound and lifesaving decisions with the most accurate, up-to-date medical information available.  In addition, with MedeFile, members enjoy the peace of mind that comes from knowing that their medical records are protected from fire, natural disaster, document misplacement or the closing of a medical or dental practice.
	MedeFile believes it enjoys a number of competitive advantages over other firms within the medical records marketplace, including:
	·	MedeFile has developed products and services geared to the patient, while containing the depth and breadth of information required by treating physicians and medical personnel.
	·	MedeFile does all the work of collecting and updating medical information on an ongoing basis; the function of our products’ dependence on the patient taking action is minimal – particularly when compared to patient action required to support competing solutions.
	·	MedeFile provides a complete medical record. Other companies claim complete longitudinal records, but in reality only provide histories (usually completed by the member/patient), which are by no means complete or necessarily accurate records.
	·	MedeFile provides a coherent mix of services and products that are intended to improve the quality of healthcare by enabling the patient to manage and access the information normally retained by doctors and other care providers.
Going Concern	Going Concern
	The accompanying financial statements have been prepared contemplating a continuation of the Company as a going concern. However, the Company has reported an operating loss of $577,175 and net income of $341,554 for the year ended December 31, 2014. During the comparable year ended 2013, the Company had an operating loss of $922,790 and net income of $1,427,251, as a direct result of the change in valuation of the Company’s warrant derivative. The Company had an accumulated deficit of $27,354,543 as of December 31, 2014.  The Company has negative working capital of $97,315 as of December 31, 2014.
	The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The operating losses raise substantial doubt about the Company's ability to continue as a going concern. The Company's ability to obtain additional financing depends on the availability of its borrowing capacity, the success of its growth strategy and its future performance, each of which is subject to general economic, financial, competitive, legislative, regulatory, and other factors beyond the Company's control.
	We will need additional investments in order to continue operations to cash flow break even. Additional investments are being sought, but we cannot guarantee that we will be able to obtain such investments. Financing transactions may include the issuance of equity or debt securities, obtaining credit facilities, or other financing mechanisms.
	However, the trading price of our common stock could make it more difficult to obtain financing through the issuance of equity or debt securities. Even if we are able to raise the funds required, it is possible that we could incur unexpected costs and expenses, fail to collect significant amounts owed to us, or experience unexpected cash requirements that would force us to seek alternative financing. Further, if we issue additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our common stock. If additional financing is not available or is not available on acceptable terms, we will have to curtail our operations.
Cash and Cash Equivalents	Cash and Cash Equivalents
	For purposes of these financial statements, cash and cash equivalents includes highly liquid debt instruments with maturity of less than three months.
Concentrations of Credit Risk	Concentrations of Credit Risk
	Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit. Currently our operating account is not above the FDIC limit.
Advertising	Advertising
	The Company follows the policy of charging the costs of advertising to expense as incurred. The Company incurred advertising costs for the year ended December 31, 2014 and 2013 of approximately $0 and $0 respectively.
Income Taxes	Income Taxes
	The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.
	The Company records net deferred tax assets to the extent the Company believes these assets will more likely than not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. A valuation allowance is established against deferred tax assets that do not meet the criteria for recognition. In the event the Company were to determine that it would be able to realize deferred income tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes.
	The Company follows the accounting guidance which provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more-likely-than-not recognition threshold at the effective date to be recognized initially and in subsequent periods. Also included is guidance on measurement, recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.
Property and Equipment	Property and Equipment
	Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. Minor additions and renewals are expensed in the year incurred. Major additions and renewals are capitalized and depreciated over their estimated useful lives being 3 years up to 10 years.
Trademark Costs	Trademark Costs
	Trademark costs incurred in the registration and acquisition of trademarks and trademark rights are capitalized. These costs will be amortized over the legal life of the related trademark once the trademark is awarded. The Company performs an annual review of its identified intangible assets to determine if facts and circumstances exist which indicate that the useful life is shorter than originally estimated or that the carrying amount of the assets may not be recoverable.
	The Company expenses all software costs associated with the conceptual formulation and evaluation of alternatives until the application development stage has been reached. Costs to improve or support the technology are expensed as these costs are incurred.
Website Development	Website Development
	The Company's policy is to capitalize website development costs at original cost and amortize the balance over the life of the product. The life of website is determined at completion of the project. The Company reviews the amounts capitalized for impairment whenever events or circumstances indicate that the carrying amounts of the assets may not be recoverable.
	The Company expenses all development costs associated with the conceptual formulation and evaluation of alternatives until the application development stage has been reached. Costs to improve or support the technology are expensed as these costs are incurred.
Revenue Recognition	Revenue Recognition
	The Company generates revenue from licensing the right to utilize its proprietary software for the storage and distribution of healthcare information to individuals and affinity groups. For revenue from product sales, the Company recognizes revenue on four basic criteria which must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management's judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.
Deferred Revenue	Deferred Revenue
	The Company generally receives subscription fees for its services. From time to time, the Company will receive quarterly or annual subscriptions paid in advance and deferred revenue is recorded at that time. The deferred revenue is amortized into revenue on a pro- rata basis each month. Customers with quarterly or annual subscriptions may cancel their subscriptions and request a refund for future months' revenues at any time. Therefore, a liability is recorded to reflect the amounts that are potentially refundable. At December 31, 2014 and December 31, 2013, deferred revenue totaled $684 and $2,075, respectively.
Reclassifications	Reclassifications
	Certain reclassifications have been made in prior periods financial statements to conform to classifications used in the current period.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In August 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Updates (ASU) 2014-15 requiring an entity’s management to evaluate whether there are conditions or events, considered in aggregate, that raise substantial doubt about entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	Cash and Equivalents, Deposits In-Transit, Receivables, Prepaid and Other Current Assets, Accounts Payable, Accrued Salaries and Wages and Other Current Liabilities
	The carrying amounts of these items approximated fair value.
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, Financial Accounting Standards Board (“FASB”) ASC Topic 820-10-35 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurements).
	Level 1—Valuations based on quoted prices for identical assets and liabilities in active markets.
	Level 2—Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.
	Level 3—Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.
	The application of the three levels of the fair value hierarchy under Topic 820-10-35 to our assets and liabilities are described below:
					Fair Value Measurements
					Level 1		Level 2		Level 3	Total
			Assets
			Website development	$	-	$	-	$	265,792	$265,792
			Total	$	-	$	-	$	265,792	$265,792
			Liabilities
			Deferred Revenues	$	684	$	-	$	-	$684
			Derivative Liability		-		-		51	51
			Total	$	684	$	-	$	51	$735
Impairment of Long Lived Assets	Impairment of Long Lived Assets
	In accordance with Accounting Standards Codification (“ASC”) 360-10, Accounting for the Impairment or Disposal of Long-Lived Assets, long-lived assets to be held and used are analyzed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. ASC 360-10 relates to assets that can be amortized and the life can be determinable. The Company reviews property and equipment and other long-lived assets for impairment annually, or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the asset’s carrying amount to future undiscounted net cash flows the assets are expected to generate. Cash flow forecasts are based on trends of historical performance and management's estimate of future performance, giving consideration to existing and anticipated competitive and economic conditions. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future cash flows arising from the assets or their fair values, whichever is more determinable.
Inventory	Inventory
	Inventories are stated at the lower of cost or market value. Cost is determined by the first-in, first-out basis and market being determined as the lower of replacement cost or net realizable value. The Company records inventory write-downs for estimated obsolescence of unmarketable inventory based upon assumptions about future demand and market conditions. For the year ended December 31, 2014 the Company had an inventory write off of $30,000. There was no inventory write off for the year ended December 31, 2013.
Net Loss per Share	Net Loss per Share
	Basic and diluted loss per share amounts are computed based on net loss divided by the weighted average number of common shares outstanding. Warrants to purchase 3,010,511 common shares were not included in the computation of diluted loss per share because the assumed conversion and exercise would be anti-dilutive for the year ending December 31, 2014.
Management Estimates	Management Estimates
	The presentation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported period. Actual results could differ from those estimates.
Stock Based Compensation	Stock Based Compensation
	The Company accounts for all compensation related to stock, options or warrants using a fair value based method whereby compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. The Company uses the Black-Scholes pricing model to calculate the fair value of options and warrants issued to both employees and non-employees. Stock issued for compensation is valued using the market price of the stock on the date of the related agreement.

Basis_of_Presentation_and_Natu2

Basis of Presentation and Nature of Business Operations (Tables)	12 Months Ended
	Dec. 31, 2014
Basis of Presentation and Nature of Business Operations [Abstract]
Schedule of three levels of the fair value hierarchy to assets and liabilities				Fair Value Measurements
				Level 1		Level 2		Level 3	Total
		Assets
		Website development	$	-	$	-	$	265,792	$265,792
		Total	$	-	$	-	$	265,792	$265,792
		Liabilities
		Deferred Revenues	$	684	$	-	$	-	$684
		Derivative Liability		-		-		51	51
		Total	$	684	$	-	$	51	$735

Website_Development_Tables

Website Development (Tables)	12 Months Ended
	Dec. 31, 2014
Website Development [Abstract]
Schedule of website development			December 31,			31-Dec-13
			2014
	Website development	$	324,285		$	224,946
	Additional development		4,453			99,340
	Accumulated amortization		(62,946	)		(62,946	)
	Net website development	$	265,792		$	261,340

Furniture_and_Equipment_Tables

Furniture and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Furniture and Equipment [Abstract]
Schedule of furniture and equipment		31-Dec-14			December 31,
					2013
	Computers and equipment	$	169,286		$	169,286
	Furniture and fixtures		38,618			38,618
	Subtotal		207,904			207,904
	Less: accumulated depreciation		(207,904	)		(207,491	)
	Net furniture and equipment	$	-		$	413

Convertible_Debebture_Related_1

Convertible Debebture - Related Party (Tables)	12 Months Ended
	Dec. 31, 2014
Convertible Debebture - Related Party [Abstract]
Schedule of convertible debentures		31-Dec-14		December 31,
				2013
	Convertible debenture – related party	$	122,538	$	111,013
	Beneficial conversion feature		-		(101,836	)
	Convertible debenture, net of BCF	$	122,538	$	9,177

Warrant_Liability_Tables

Warrant Liability (Tables)	12 Months Ended
	Dec. 31, 2014
Class of Warrant or Right [Line Items]
Schedule of Transactions involving warrants
		Number of Warrants			Weighted-Average Price Per Share
	Outstanding at December 31, 2011		3,008,511		$	0.5
	Granted
	Exercised
	Canceled or expired
	Additional due to ratchet trigger
	Outstanding at December 31, 2013		3,008,511			0.5
	Granted
	Exercised
	Canceled or expired
	Addition due to ratchet trigger
	Outstanding at December 31, 2014		3,008,511		$	0.5
Schedule of warrant liability		31-Dec-14			December 31,
					2013
	Warrant liability (beginning balance)	$	5,618,819		$	5,618,819
	Additional liability due to new grants
	Loss(gain) on changes in fair market value of warrant liability		(5,618,768	)		(4,556,678	)
	Net warrant liability	$	51		$	1,062,141
Warrants granted during July 2011 [Member]
Class of Warrant or Right [Line Items]
Schedule of fair value assumptions for warrants
		Grant Date			31-Dec-14
	Risk-free interest rate at grant date		1.21	%		1.38	%
	Expected stock price volatility		194.9	%		143.1	%
	Expected dividend payout		-			-
	Expected option in life-years		4			51
Warrants granted during April 2012 [Member]
Class of Warrant or Right [Line Items]
Schedule of fair value assumptions for warrants
		Grant Date			31-Dec-14
	Risk-free interest rate at grant date		0.63	%		0	%
	Expected stock price volatility		174.8	%		143.1	%
	Expected dividend payout		-			-
	Expected option in life-years		4			1.3
Warrants granted during April 2012 [Member] | Shareholder and Brother of Chief Executive Officer [Member]
Class of Warrant or Right [Line Items]
Schedule of fair value assumptions for warrants
		Grant Date			31-Dec-14
	Risk-free interest rate at grant date		0.64	%		0	%
	Expected stock price volatility		174.3	%		143.1	%
	Expected dividend payout		-			-
	Expected option in life-years		4			1.28

Equity_Tables

Equity (Tables)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Schedule of estimated value of the compensatory warrants granted to non-employees in exchange for services and financing expenses	Risk-free interest rate at grant date		4.75	%
	Expected stock price volatility		155	%
	Expected dividend payout		--
	Expected option in life-years		5
	Risk-free interest rate at grant date		0.39	%
	Expected stock price volatility		172.1	%
	Expected dividend payout		--
	Expected option in life-years		4
Schedule of warrants transactions		Number of Warrants			Weighted-Average Price Per Share
	Outstanding at December 31, 2012		29,000			30.07
	Granted		-			-
	Exercised		-			-
	Canceled or expired		-			-
	Outstanding at December 31, 2013		29,000		$	26.72
	Granted		-			-
	Exercised		-			-
	Canceled or expired		-27,000			25
	Outstanding at December 31, 2014		2,000		$	50
Schedule of outstanding warrants	Warrants Outstanding
					Weighted
					Average
					Remaining
	Exercise	Number			Contractual
	Prices		Outstanding			Life (years)
	$50		2,000			0.75
	50		2,000			0.75

Basis_of_Presentation_and_Natu3

Basis of Presentation and Nature of Business Operations - Fair value hierarchy to our assets and liabilities (Details) (USD $)	Dec. 31, 2014
Level 1
Assets
Website development
Total
Liabilities
Deferred Revenues	684
Derivative Liability
Total	684
Level 2
Assets
Website development
Total
Liabilities
Deferred Revenues
Derivative Liability
Total
Level 3
Assets
Website development	265,792
Total	265,792
Liabilities
Deferred Revenues
Derivative Liability	51
Total	51
Total Fair Value
Assets
Website development	265,792
Total	265,792
Liabilities
Deferred Revenues	684
Derivative Liability	51
Total	$735

Basis_of_Presentation_and_Natu4

Basis of Presentation and Nature of Business Operations (Detail Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Basis of Presentation and Nature of Business Operations [Abstract]
Income (loss)	$341,554	$1,427,251
Accumulated deficit	-27,354,543	-27,696,097
Net working capital deficit	97,315
Deferred revenues	684	2,075
Advertising costs	0	0
Operating Income (Loss)	($577,175)	($929,790)

Basis_of_Presentation_and_Natu5

Basis of Presentation and Nature of Business Operations (Detail Textual 1)	12 Months Ended
	Dec. 31, 2014
Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful lives	10 years
Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful lives	3 years

Basis_of_Presentation_and_Natu6

Basis of Presentation and Nature of Business Operations (Detail Textual 2) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Loss on write-off of inventory	$30,000
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	3,010,511

Website_Development_Summary_of

Website Development - Summary of website development (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	($62,946)	($62,946)
Net website development	265,792	261,340
Website development
Finite-Lived Intangible Assets [Line Items]
Website development	324,285	224,946
Additional development
Finite-Lived Intangible Assets [Line Items]
Website development	$4,453	$99,340

Website_Development_Detail_Tex

Website Development (Detail Textuals) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Website Development [Abstract]
Amortization	$1,339	$5,245
Finite lived intangible assets, amortization period	3 years

Furniture_and_Equipment_Summar

Furniture and Equipment - Summary of furniture and equipment (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Subtotal	$207,904	$207,904
Less: accumulated depreciation	-207,904	-207,491
Net furniture and equipment		413
Computers and equipment [Member]
Property, Plant and Equipment [Line Items]
Subtotal	169,286	169,286
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Subtotal	$38,618	$38,618

Furniture_and_Equipment_Detail

Furniture and Equipment (Detail Textuals) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Furniture and Equipment [Abstract]
Depreciation	$413	$1,116

Convertible_Debebture_Related_2

Convertible Debebture - Related Party (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Convertible Debebture - Related Party [Abstract]
Convertible debenture - related party	$122,538	$111,013
Beneficial conversion feature		-101,836
Convertible debenture, net of BCF	$122,538	$9,177

Convertible_Debebture_Related_3

Convertible Debebture - Related Party (Details Textual) (Secured Convertible Debentures [Member], USD $)	1 Months Ended	0 Months Ended	12 Months Ended
	Dec. 17, 2013	Nov. 04, 2013	Dec. 31, 2014
			debentures
Secured Convertible Debentures [Member]
Short-term Debt [Line Items]
Terms of conversion feature	One year	One year
Convertible debenture Issued	$60,000	$50,000
Convertible conversion Price	$0.10	$0.10
Secured Convertible Debentures interest rate			10.00%
Number of Secured Convertible Debentures			2

Warrant_Liability_Summary_of_f

Warrant Liability - Summary of fair value of warrants (Details)	1 Months Ended	12 Months Ended	1 Months Ended
	Jul. 31, 2011	Dec. 31, 2014	Apr. 30, 2012
Warrants granted during July 2011 [Member]
Class of Warrant or Right [Line Items]
Risk-free interest rate at grant date	1.21%	1.38%
Expected stock price volatility	194.90%	143.10%
Expected dividend payout
Expected option in life-years	4 years	51 years
Warrants granted during April 2012 [Member]
Class of Warrant or Right [Line Items]
Risk-free interest rate at grant date		0.00%	0.63%
Expected stock price volatility		143.10%	174.80%
Expected dividend payout
Expected option in life-years		1 year 3 months 18 days	4 years
Warrants granted during April 2012 [Member] | Shareholder and Brother of Chief Executive Officer [Member]
Class of Warrant or Right [Line Items]
Risk-free interest rate at grant date		0.00%	0.64%
Expected stock price volatility		143.10%	174.30%
Expected dividend payout
Expected option in life-years		1 year 3 months 11 days	4 years

Warrant_Liability_Summary_of_t

Warrant Liability - Summary of transactions involving warrants (Details 1) (Warrants with ratchet provisions, USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Warrants with ratchet provisions
Warrant Outstanding [Roll Forward]
Number of Warrants, Outstanding, Beginning	3,008,511	3,008,511
Number of Warrants, Granted
Number of Warrants, Exercised
Number of Warrants, Canceled or expired
Additional due to ratchet trigger
Number of Warrants, Outstanding, Ending	3,008,511	3,008,511
Warrants Outstanding Weighted Average Price Per Share [Roll Forward]
Weighted-Average Price Per Share, Outstanding	0.5	0.5
Weighted average price per share, Granted
Weighted average price per share, Exercised
Weighted average price per share, Canceled or expired
Additional due to ratchet trigger
Weighted-Average Price Per Share, Outstanding	0.5	0.5

Warrant_Liability_Summary_of_w

Warrant Liability - Summary of warrant liability (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Fair Value of Warrant Liability [Roll Forward]
Warrant liability (beginning balance)	$1,062,141	$5,618,819
Additional liability due to new grants
Loss(gain) on changes in fair market value of warrant liability	-5,618,768	-4,556,678
Net warrant liability	$51	$1,062,141

Warrant_Liability_Detail_Textu

Warrant Liability (Detail Textuals) (USD $)	12 Months Ended		1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jul. 31, 2011	Apr. 30, 2012
Class of Warrant or Right [Line Items]
Term of warrants expired from date of grant	4 years
Company granted the additional shares of common stock period	2 years
Method used for fair value of warrant granted	Black Scholes pricing model
Loss (gain) on changes in fair market value of warrant liability	$1,062,090	$2,366,218
Warrants granted during July 2011 [Member] | Common Stock
Class of Warrant or Right [Line Items]
Number of stock sold (in shares)			35,461
Number of share stock called by warrants			35,461
Exercise price of warrants (in dollars per share)			$2.50
Warrants granted during April 2012 [Member] | Common Stock
Class of Warrant or Right [Line Items]
Number of stock sold (in shares)				1,000,000
Number of share stock called by warrants				1,808,511
Exercise price of warrants (in dollars per share)				$0.50
Warrants granted during April 2012 [Member] | Shareholder and Brother of Chief Executive Officer [Member] | Common Stock
Class of Warrant or Right [Line Items]
Number of stock sold (in shares)				100,000
Number of share stock called by warrants				200,000
Exercise price of warrants (in dollars per share)				$0.50

Equity_Fair_value_assumptions_

Equity - Fair value assumptions (Details) (Common Stock Warrants [Member])	12 Months Ended
	Dec. 31, 2014
Former Board Members [Member]
Class of Warrant or Right [Line Items]
Risk-free interest rate at grant date	4.75%
Expected stock price volatility	155.00%
Expected dividend payout
Expected option in life-years	5 years
Consultant [Member]
Class of Warrant or Right [Line Items]
Risk-free interest rate at grant date	0.39%
Expected stock price volatility	172.10%
Expected dividend payout
Expected option in life-years	4 years

Equity_Transactions_involving_

Equity - Transactions involving warrants (Details 1) (Warrant [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Warrant [Member]
Class of Warrant or Right [Line Items]
Beginning balance	29,000	29,000
Granted
Exercised
Canceled or expired	-27,000
Ending balance	2,000	29,000
Weighted average price per share, Beginning balance	$26.72	$30.07
Weighted average price per share, Granted
Weighted average price per share, Exercised
Weighted average price per share, Canceled or expired	$25
Weighted average price per share, Ending balance	$50	$26.72

Equity_Warrants_Outstanding_De

Equity - Warrants Outstanding (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2014
Exercise Price $ 50 [Member]
Warrants Outstanding
Exercise price of warrants (in dollars per share)	$50
Warrants Outstanding, Number Outstanding	2,000
Warrants Outstanding, Weighted Average Remaining Contractual Life	9 months
Exercise Prices 50 [Member]
Warrants Outstanding
Exercise price of warrants (in dollars per share)	$50
Warrants Outstanding, Number Outstanding	2,000
Warrants Outstanding, Weighted Average Remaining Contractual Life	9 months

Equity_Detail_Textuals

Equity (Detail Textuals)	0 Months Ended
	Oct. 08, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 19, 2013
Reverse split of common stock	5,000-to-1
Common stock, shares authorized		500,000,000	500,000,000
Common Stock [Member]
Common stock, shares authorized	75,000,000,000	100,000,000	500,000,000	100,000,000

Equity_Detail_Textuals_1

Equity (Detail Textuals 1) (USD $)	1 Months Ended	0 Months Ended	1 Months Ended	0 Months Ended		1 Months Ended
	Apr. 17, 2014	1-May-13	Jan. 17, 2013	Jul. 06, 2014	Jul. 03, 2014	Dec. 17, 2013	Dec. 20, 2013	Sep. 23, 2013	Aug. 27, 2013	Apr. 15, 2013
Security Purchase Agreement [Member]
Number of stock sold (in shares)	24,545,455	11,872,281	400,000
Aggregate purchase price of common stock sold			$200,000
Security Purchase Agreement [Member] | Accredited Investors [Member]
Number of stock sold (in shares)				20,000,000	15,000,000	2,000,000	15,000,000	21,429	42,743	2,000,000
Aggregate purchase price of common stock sold				$150,000	$200,000	$40,000	$300,000	$15,000	$29,920	$400,000
Lyle Hauser [Member]
Number of stock sold (in shares)	125,584,200
Lyle Hauser [Member] | Security Purchase Agreement [Member]
Number of stock sold (in shares)	150,129,655

Equity_Detail_Textuals_2

Equity (Detail Textuals 2) (USD $)	12 Months Ended	1 Months Ended	0 Months Ended			1 Months Ended
	Dec. 31, 2014	Apr. 17, 2014	Apr. 10, 2012	Apr. 12, 2012	1-May-13	Jan. 17, 2013	Dec. 31, 2013
Schedule Of Equity [Line Items]
Preferred stock designated as Series B Convertible Preferred Stock	10,000,000						10,000,000
Number of shares of common stock reserved for issuance	10,000,000
Number of options granted to employees	5,640,000
Lyle Hauser [Member]
Schedule Of Equity [Line Items]
Number of stock sold (in shares)		125,584,200
Series B Preferred Stock [Member]
Schedule Of Equity [Line Items]
Preferred stock designated as Series B Convertible Preferred Stock			100,000
Liquidation preference stated value			$1
Number of votes entitled to be cast			0.00%
Total percentage of number of votes entitled to be cast per share			51.00%
Common stock for each share of Series B Preferred Stock			2
Number of preferred stock converted				100,000
Shares issued upon conversion of preferred stock				200,000
Security Purchase Agreement [Member]
Schedule Of Equity [Line Items]
Shares issued, value						$200,000
Number of stock sold (in shares)		24,545,455			11,872,281	400,000
Security Purchase Agreement [Member] | Lyle Hauser [Member]
Schedule Of Equity [Line Items]
Number of stock sold (in shares)		150,129,655
Security Purchase Agreement [Member] | Series B Preferred Stock [Member] | Lyle Hauser [Member]
Schedule Of Equity [Line Items]
Shares issued, value				100,000
Number of stock sold (in shares)				100,000
Warrants issued to purchase common stock to the investor				200,000
Warrants Outstanding, Exercise Price				0.5
Term of warrants				4 years

Equity_Detail_Textuals_3

Equity (Detail Textuals 3) (USD $)	12 Months Ended		1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jul. 28, 2011	Jun. 22, 2011
Former Board Members [Member]
Class of Warrant or Right [Line Items]
Number of warrants awarded	35
Warrants Outstanding, Exercise Price	$2,800
Term of warrants	5 years
Method used for fair value of the warrants	Black-Scholes pricing model
Warrant [Member]
Class of Warrant or Right [Line Items]
Number of warrants awarded
Warrant [Member] | Consultants
Class of Warrant or Right [Line Items]
Number of warrants awarded			27,000	2,000
Warrants Outstanding, Exercise Price			$25	$50
Term of warrants			3 years	4 years
Method used for fair value of the warrants			Black-Scholes pricing model	Black-Scholes pricing model

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	1 Months Ended	0 Months Ended	1 Months Ended	3 Months Ended
	Apr. 17, 2014	1-May-13	Jan. 17, 2013	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Feb. 10, 2015
Subsequent Event [Line Items]
Common stock, shares authorized					500,000,000	500,000,000
Lyle Hauser
Subsequent Event [Line Items]
Aggregate purchase price of common stock issued (in shares)	125,584,200
Security Purchase Agreement [Member]
Subsequent Event [Line Items]
Aggregate purchase price of common stock issued (in shares)	24,545,455	11,872,281	400,000
Aggregate purchase price of common stock issued			$200,000
Security Purchase Agreement [Member] | Lyle Hauser
Subsequent Event [Line Items]
Aggregate purchase price of common stock issued (in shares)	150,129,655
Subsequent Event [Member]
Subsequent Event [Line Items]
Common stock, shares authorized							700,000,000
Subsequent Event [Member] | Lyle Hauser
Subsequent Event [Line Items]
Common stock issued in exchange of debt (in shares)				18,018,018
Common stock issued in exchange of debt				40,000
Subsequent Event [Member] | Security Purchase Agreement [Member]
Subsequent Event [Line Items]
Aggregate purchase price of common stock issued (in shares)				279,099,100
Aggregate purchase price of common stock issued				$620,000